Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 6:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 553 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Vein Thrombosis Clear all
Completed Phase 1 Interventional

The UNBLOCK Study: Utilization of Bivalirudin On Clots in Kids

NCT00812370
View directory record Official record
Conditions
Deep Venous Thrombosis
Interventions
Bivalirudin
Drug
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
6 Months to 18 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
6
States / cities
Los Angeles, California • Aurora, Colorado • Columbus, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2016 · Synced Oct 15, 2026, 6:53 AM EDT
Completed Phase 4 Interventional Results available

Fondaparinux in Critically Ill Patients With Renal Failure

NCT01467583
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Fondaparinux
Drug
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 89 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 19, 2015 · Synced Oct 15, 2026, 6:53 AM EDT
Completed Phase 4 Interventional Results available

Apixaban for the Acute Treatment of Venous Thromboembolism in Children

NCT02464969
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Apixaban, Standard of Care
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
0 Days to 17 Years
Enrollment
229 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
84
States / cities
Birmingham, Alabama • Phoenix, Arizona • Loma Linda, California + 47 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2024 · Synced Oct 15, 2026, 6:53 AM EDT
Completed No phase listed Observational

The Roles of Tissue Factor in Malignant Gliomas

NCT00201903
View directory record Official record
Conditions
Venous Thromboembolism, Brain Tumors
Interventions
Not listed
Lead sponsor
Ontario Clinical Oncology Group (OCOG)
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
2
States / cities
Detroit, Michigan • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 6, 2017 · Synced Oct 15, 2026, 6:53 AM EDT
Completed No phase listed Observational

Characterizing Recurrent Thromboembolism, Major Bleeding and All-Cause Death in Patients With Cancer-Associated Thromboembolism Treated With Rivaroxaban

NCT03214172
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Rivaroxaban (Xarelto, BAY59-7939)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 6, 2018 · Synced Oct 15, 2026, 6:53 AM EDT
Active, not recruiting Phase 3 Interventional

A 3-month Study to Compare the Safety of ONS-5010 in Vials Versus Pre-filled Syringe in Subjects With Visual Impairment Due to Retinal Disorders

NCT05112861
View directory record Official record
Conditions
Age-Related Macular Degeneration, Neovascular Age-related Macular Degeneration, Wet Macular Degeneration, BRVO - Branch Retinal Vein Occlusion, Diabetic Macular Edema
Interventions
bevacizumab
Biological
Lead sponsor
Outlook Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
3
States / cities
Springfield, Illinois • Hagerstown, Maryland • Chambersburg, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 15, 2026, 6:53 AM EDT
Completed Phase 4 Interventional

Apixaban vs Rivaroxaban vs No Anticoagulant to Prevent EHIT After Great Saphenous Vein Laser Ablation

NCT07699796
View directory record Official record
Conditions
Venous Thrombosis Deep (Limbs), Venous Insufficiency (Chronic)(Peripheral), Varicose Veins Leg, Venous Thrombosis
Interventions
Apixaban, Rivaroxaban
Drug
Lead sponsor
Heart, Artery, and Vein Center of Fresno
Other
Eligibility
18 Years and older
Enrollment
564 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Fresno, California
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 15, 2026, 6:53 AM EDT
Completed Phase 3 Interventional Results available

Switching Drug Therapy for the Prevention of Blood Clot Formation From Enoxaparin to Rivaroxaban After Orthopedic Surgery for Either Total Hip or Total Knee Replacement

NCT01094886
View directory record Official record
Conditions
Arthritis, Osteoarthritis, Knee, Osteoarthritis, Hip, Thromboembolism
Interventions
Rivaroxaban
Drug
Lead sponsor
Ortho-McNeil Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
5
States / cities
Denver, Colorado • Hollywood, Florida • Tamarac, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2017 · Synced Oct 15, 2026, 6:53 AM EDT
Completed No phase listed Observational

Quantra Determination of Coagulation Parameters in Arterial and Venous Blood

NCT02978872
View directory record Official record
Conditions
Cardiac Surgery
Interventions
Not listed
Lead sponsor
HemoSonics LLC
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 19, 2017 · Synced Oct 15, 2026, 6:53 AM EDT
Completed No phase listed Observational

Risk Factors for Venous Thromboembolism in the Community

NCT00011180
View directory record Official record
Conditions
Cardiovascular Diseases, Thromboembolism
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
Not listed
Enrollment
385 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 6, 2012 · Synced Oct 15, 2026, 6:53 AM EDT
Recruiting No phase listed Observational

Filter Initial & Long Term Evaluation After Placement and Retrieval Registry

NCT01158482
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
IVC Filter Placement or Retrieval
Procedure
Lead sponsor
Stanford University
Other
Eligibility
Not listed
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2030
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Sep 26, 2025 · Synced Oct 15, 2026, 6:53 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

OsciPulse Device for the Prevention of VTE

NCT04625673
View directory record Official record
Conditions
Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Thromboembolisms
Interventions
OsciPulse
Device
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 28, 2023 · Synced Oct 15, 2026, 6:53 AM EDT
Enrolling by invitation Phase 4 Interventional

Study Evaluating the Efficacy and Safety of Chloroprocaine HCl Ophthalmic Gel 3% vs Proparacaine Ophthalmic Solution 0.5% Plus Subconjunctival Lidocaine in Patients Undergoing Intravitreal Injections

NCT07456826
View directory record Official record
Conditions
Diabetic Macular Edema (DME), Age-Related Macular Degeneration (AMD), Retinal Vein Occlusion, Diabetic Retinopathy (DR)
Interventions
Chloroprocaine Ophthalmic Gel 3% (IHEEZO), Sham Subconjunctival Injection, Proparacaine Hydrochloride Ophthalmic Solution 0.5%, Lidocaine Hydrochloride Injection 2%
Drug · Procedure
Lead sponsor
Harrow Inc
Industry
Eligibility
18 Years and older
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Tyler, Texas
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Oct 15, 2026, 6:53 AM EDT
Terminated Phase 4 Interventional Results available

Calf Deep Vein Thrombosis Treatment Trial

NCT03590743
View directory record Official record
Conditions
Deep Vein Thrombosis
Interventions
Apixaban, Placebo
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
3
States / cities
Rochester, Minnesota • Eau Claire, Wisconsin • La Crosse, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 25, 2020 · Synced Oct 15, 2026, 6:53 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study to Assess the Safety, Pharmacokinetics/Dynamics of DS-1040b in Subjects With Acute Submassive Pulmonary Embolism

NCT02923115
View directory record Official record
Conditions
Pulmonary Embolism, Thrombotic Disease
Interventions
DS-1040b, Placebo, Enoxaparin
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 75 Years
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
15
States / cities
Mobile, Alabama • Beverly Hills, California • San Diego, California + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2023 · Synced Oct 15, 2026, 6:53 AM EDT
Completed Phase 2 Interventional Results available

Oral Apixaban (Eliquis) Versus Enoxaparin (Lovenox) for Thromboprophylaxis in Women With Suspected Pelvic Malignancy

NCT02366871
View directory record Official record
Conditions
Gynecologic Cancer, Venous Thromboembolism
Interventions
Oral apixaban, Subcutaneous enoxaparin
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 89 Years · Female only
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
Los Angeles, California • Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 31, 2020 · Synced Oct 15, 2026, 6:53 AM EDT
Completed No phase listed Observational

Total Knee Arthroplasty And Thromboembolism: A Comparison Between Two Surgical Techniques

NCT00755300
View directory record Official record
Conditions
Total Knee Replacement, Venous Thromboembolism
Interventions
Measurement of total thrombolic load
Procedure
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Aug 15, 2011 · Synced Oct 15, 2026, 6:53 AM EDT
Terminated No phase listed Observational

Comparison of the Risk of Venous Thromboembolism (i.e., Blood Clots in the Veins) and Bleeding Events in a Population of Obese Patients Receiving Higher-Dose or Extended-Duration Versus Conventional-Dose or Conventional-Duration of Prophylaxis (i.e., Preventive Treatment) With Enoxaparin

NCT05819125
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Not listed
Lead sponsor
Sanofi
Industry
Eligibility
40 Years and older
Enrollment
21,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 29, 2024 · Synced Oct 15, 2026, 6:53 AM EDT
Completed Not applicable Interventional Results available

Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer

NCT02744092
View directory record Official record
Conditions
Cancer, Venous Thromboembolism, Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Blood Clot
Interventions
Rivaroxaban, Apixaban, Edoxaban, Dabigatran, Warfarin, Dalteparin, Enoxaparin, Fondaparinux
Drug
Lead sponsor
Alliance Foundation Trials, LLC.
Other
Eligibility
18 Years and older
Enrollment
811 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
151
States / cities
Chula Vista, California • Fremont, California • Fresno, California + 104 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2023 · Synced Oct 15, 2026, 6:53 AM EDT
Recruiting No phase listed Observational

Vascular Lab Resource (VLR) Biorepository

NCT05628948
View directory record Official record
Conditions
Cardiovascular Diseases, Metabolic Disease, Peripheral Artery Disease, Carotid Disease, Aneurysmal Disease, Venous Disease, Thrombosis, Lymphedema, Lipedema, Non-Atherosclerotic Chronic Arterial Occlusive Disease, Vasculitis, Fibromuscular Dysplasia, Arterial Dissection, May-Thurner Syndrome, Thoracic Outlet Syndrome, Vasospasm
Interventions
Not listed
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
500 participants
Timeline
2019 – 2031
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 19, 2025 · Synced Oct 15, 2026, 6:53 AM EDT
Completed Phase 2 Interventional

Detecting the Impact of Statin Therapy On Lowering Risk of Venous Thrombo-Embolic Events (DISOLVE)

NCT01524653
View directory record Official record
Conditions
Venous Thromboembolism, Deep Vein Thrombosis, Neoplasms
Interventions
Rosuvastatin, Placebo
Drug
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Jul 10, 2018 · Synced Oct 15, 2026, 6:53 AM EDT
Completed Not applicable Interventional

Doppler Ultrasound Following Unicondylar Knee Replacement to Determine the Incidence of Postoperative DVT

NCT02148757
View directory record Official record
Conditions
Number of Deep Venous Thrombosis (DVT)
Interventions
Doppler Ultrasound
Procedure
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
Not listed
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 21, 2017 · Synced Oct 15, 2026, 6:53 AM EDT
Not listed Phase 1 Interventional

Phase I Study of Episcleral Celecoxib for Treatment of Macular Edema and Inflammatory Disorders of the Posterior Pole

NCT04120636
View directory record Official record
Conditions
Macula Edema, Radiation Retinopathy, Branch Retinal Vein Occlusion, Epiretinal Membrane, Central Serous Retinopathy With Pit of Optic Disc, Commotio Retinae, Vitritis
Interventions
Episcleral Celecoxib
Drug
Lead sponsor
Targeted Therapy Technologies, LLC
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Nov 24, 2023 · Synced Oct 15, 2026, 6:53 AM EDT
Not listed No phase listed Observational

Effectiveness of Blood Clot Medication With Concomitant Blood Pressure Medication

NCT00424281
View directory record Official record
Conditions
ICU Patients 18 Years or Older.
Interventions
Arixtra (fondaparinux), 2.5 mg/day-what is bioavailability
Drug
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 19, 2007 · Synced Oct 15, 2026, 6:53 AM EDT